Digital Day One

Hear cutting edge presentations delivered by AgenTus, Fate Therapeutics, NK Max America, FDA & Cytovia Therapeutics across 3 dedicated tracks to address:

  • The future for innate therapies – ask your questions during the Industry Leader’s Fireside Chat to hear the C-level leaders’ opinions on gene engineering, allogeneic drug development, solid tumors and future commercialization
  • Gene engineering strategies including CAR-NK and TRAIL variants to develop more resilient, persistence and targeted NK cells
  • Innovative process development to achieve scalable expansion for clinical manufacture
  • Regulatory perspectives on the development of innate immune cell products from CBER, FDA

And much more!

Key speakers include:

Daniel Teper


Cytovia Therapeutics

Evren Alici



Matthew Klinker

Biologist, Cell Therapy Branch, Division of Cellular and Gene Therapies


Xiaokui Zhang



9:30 - 6:00 EDT | 6:30 - 3:00 PDT

9:30 am Online Registration & Virtual Coffee Networking

9:50 am Chair’s Opening Remarks

10:00 am Industry Leader’s Fireside Chat


An executive panel discussion from the C-level leaders of the NK space to set the scene on NK cell therapy development.

Ask your questions live to understand the expert’s thoughts on key topics including gene engineering, allogeneic drug development, optimal cell sources, driving clinical success in solid tumors and future thoughts on market access and commercialization.

11:00 am Speed Networking

12:00 pm Refreshment Break

1:20 pm Speaker Break Out Discussions

1:35 pm Refreshment Break

3:35 pm Speaker Break Out Discussions

3:50 pm Refreshment Break & Poster Session

5:00 pm Regulatory Perspectives on Development of Innate Immune Cell Products

  • Matthew Klinker Biologist, Cell Therapy Branch, Division of Cellular and Gene Therapies, CBER


  • Preparing for and submitting an investigational new drug application
  • Manufacturing considerations for early-stage studies
  • Product characterization considerations throughout development

5:25 pm Gene Editing to Enhance Function of iPSC-derived NK Cells


  • Outline improved NK cell function via deletion of ADAM17
  • Combined CIS-deletion with other gene edits to improve NK cell activity
  • Reveal novel targets that regulate NK cell-mediated activity

5:50 pm Closing remarks

6:00 pm End of Day 1